With over 44.12 million Bristol-Myers Squibb Co. (BMY) shares trading Friday and a closing price of $50.89 on the day, the dollar volume was approximately $2.25 billion. The shares have shown a negative half year performance of -23.08% and its price on 12/15/23 lost nearly -1.13%. Currently, there are 2.10B common shares owned by the public and among those 2.03B shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 27 analysts who have offered their price forecasts for BMY have a consensus price objective of $63.15. The analysts have set the share’s price value over the next 12 months at a high of $90.00 and a low of $42.00. The average price target is 19.41% above its recent price level and a downside to the estimated low will see the stock lose -21.17% over that period. But an upside of 43.46% will see the stock hit the forecast high price target while median target price for the stock is $60.00.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 140 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 86 of these insider trades were purchases, accounting for 710,591 shares. Insider sales of the common stock occurred on 54 occasions, with total insider shares sold totaling 675,313 shares.
Shares of Bristol-Myers Squibb Co. (NYSE: BMY) opened at $51.16, down -$0.31 from a prior closing price of $51.47. However, the script later moved the day high at 51.45, down -1.13%. The company’s stock has a 5-day price change of 1.15% and -13.13% over the past three months. BMY shares are trading -29.27% year to date (YTD), with the 12-month market performance down to -34.03% lower. It has a 12-month low price of $48.25 and touched a high of $77.21 over the same period. BMY has an average intraday trading volume of 13.28 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.79%, -2.92%, and -17.24% respectively.
Institutional ownership of Bristol-Myers Squibb Co. (NYSE: BMY) shares accounts for 78.78% of the company’s 2.10B shares outstanding.
It has a market capitalization of $103.55B and a beta (3y monthly) value of 0.34. The stock’s trailing 12-month PE ratio is 12.91, while the earnings-per-share (ttm) stands at $3.94. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.47% over the week and 1.97% over the month.
Analysts forecast that Bristol-Myers Squibb Co. (BMY) will achieve an EPS of $1.61 for the current quarter, $1.83 for the next quarter and $6.7 for 2024. The lowest estimate earnings-per-share for the quarter is $1.31 while analysts give the company a high EPS estimate of $1.69. Comparatively, EPS for the current quarter was $1.82 a year ago. Earnings per share for the fiscal year are expected to decrease by -2.18%, and -2.58% over the next financial year. EPS should shrink at an annualized rate of -0.25% over the next five years, compared to 37.06% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 27 brokerage firm advisors rate Bristol-Myers Squibb Co. (BMY) as a “Moderate Buy” at a consensus score of 2.48. Specifically, 8 Wall Street analysts polled rate the stock as a buy, while 16 of the 27 advise that investors “hold,” and 1 rated it as a “Sell.”
Looking at the support for the BMY, a number of firms have released research notes about the stock. Cantor Fitzgerald stated their Neutral rating for the stock in a research note on November 15, 2023, with the firm’s price target at $68-$55.
